Kinetics of p53 Binding to Promoter Sites In Vivo

Abstract

Downstream target genes of p53 are thought to mediate its tumor-suppressive activity, but it is unknown whether differential transactivation of these genes is regulated at the level of p53 binding to their promoters. To address this issue, p53 binding in vivo to consensus sites in the p21^Waf1, MDM2, and PIG3 promoters was investigated in cells exposed to adriamycin (ADR) or ionizing radiation as well as in an inducible p53 cell line. p53-DNA complexes were cross-linked in vivo by treating the cells with formaldehyde and processed by chromatin immunoprecipitation-PCR. This methodology allowed for the analysis of relevant p53-DNA complexes by preventing redistribution of cellular components upon collection of cell extracts. Increased p53 binding to the p21^Waf1, MDM2, and PIG3 promoters occurred within 2 h after p53 activation; however, significant increases in PIG3 transcription did not occur until 15 h after p53 binding. Gel shift analyses indicated that p53 had lower affinity for the consensus binding site in the PIG3 promoters compared to its consensus sites in the p21 and MDM2 genes, which suggests that additional factors may be required to stabilize the interaction of p53 with the PIG3 promoter. Further, acetylated p53 (Lys382) was found in chemically cross-linked complexes at all promoter sites examined after treatment of cells with ADR. In summary, the kinetics of p53 binding in vivo to target gene regulatory regions does not uniformly correlate with target gene mRNA expression for the p53 target genes examined. Our results suggest that target genes with low-affinity p53 binding sites may require additional events and will have delayed kinetics of induction compared to those with high-affinity binding sites.

ACKNOWLEDGMENTS

The first two authors contributed equally to this work.

We are grateful to the P. J. Farnham laboratory for helpful suggestions regarding the formaldehyde cross-linking procedure. We thank D. Hill for provision of phosphorylation- and acetylation-specific antibodies, L. J. Tang for expert technical assistance, and members of the Pietenpol laboratory and Vanderbilt-Ingram Cancer Center for critical reading of the manuscript.

This work was supported by NIH grants CA70856 (to J.A.P.) and CA68485 (core services), a Burroughs Wellcome New Investigator in Toxicology Award (to J.A.P.), NIEHS grant ES00267 (core services), and Department of the Army grant DAMD 17-97-1-7267 (to S.T.S.).